Rio, J;
Rovira, A;
Tintore, M;
Otero-Romero, S;
Comabella, M;
Vidal-Jordana, A;
Galan, I;
... Montalban, X; + view all
(2018)
Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
Multiple Sclerosis Journal
, 24
(3)
pp. 322-330.
10.1177/1352458517698052.
Preview |
Text
Tur Gomez_Rio_BetaDefinite25MSJ.pdf - Accepted Version Download (722kB) | Preview |
Abstract
Objective: To investigate the association between activity during interferon-beta (IFNβ) therapy and disability outcomes in patients with relapsing–remitting multiple sclerosis (RRMS). Methods: A longitudinal study based on two previously described cohorts of IFNβ-treated RRMS patients was conducted. Patients were classified according to clinical activity after 2 years (clinical cohort) or to clinical and radiological activity after 1 year (magnetic resonance imaging (MRI) cohort). Multivariate Cox models were calculated for early disease activity predicting long-term disability. Results: A total of 516 patients from two different cohorts were included in the analyses. Persistent clinical disease activity during the first 2 years of therapy predicted severe long-term disability (clinical cohort). In the MRI cohort, modified Rio score and no or minimal evidence of disease activity (NEDA/MEDA) did not identify patients with risk of Expanded Disability Status Scale (EDSS) worsening. However, a Rio score ≥ 2 (hazard ratio (HR): 3.3, 95% confidence interval (CI): 1.7–6.4); ≥3 new T2 lesions (HR: 2.9, 95% CI: 1.5–5.6); or ≥2 Gd-enhancing lesions (HR: 2.1, 95% CI: 1.1–4) were able to identify patients with EDSS worsening. Conclusion: Although early activity during IFNβ therapy is associated with poor long-term outcomes, minimal degree of activity does not seem to be predictive of EDSS worsening over 6.7-year mean follow-up.
| Type: | Article |
|---|---|
| Title: | Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/1352458517698052 |
| Publisher version: | http://doi.org/10.1177/1352458517698052 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Multiple sclerosis, disability, interferon-beta, treatment response, MRI, outcome measurement |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neuroinflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10063901 |
Archive Staff Only
 |
View Item |
